Guilherme Harada
@HaradaGuilherme
Followers
735
Following
473
Media
5
Statuses
121
Medical Oncologist at Hospital Sírio-Libanês, Brazil Former Advanced Oncology Fellow - Early Drug Development, @MSKCancerCenter
Joined February 2019
🚨“Rare” molecular subtypes of lung cancer: why should we care?. 📝In this review out @NatRevClinOncol, we highlight that many rare molecular subtypes of lung cancer individually account for a substantial number of patients diagnosed around the world.🧵.
1
18
73
🫁Honored to have contributed to this study . Due to its alternative type II binding mode and its broad availability, cabozantinib can be particularly useful in the treatment of resistance to type I MET TKIs. @alexdrilon .@MSK_DeptOfMed .
jtocrr.org
Only type I MET tyrosine kinase inhibitors (TKIs) are approved for treating MET-altered NSCLCs. Preclinically, type II TKIs, such as cabozantinib, can rescue progression on type I TKIs. This phase 2...
In this phase II trial evaluating the activity of #cabozantinib, Harada et al. demonstrated that this treatment could benefit pts w MET-altered lung cancers previously treated with type I MET TKIs. Read more:
2
1
20
RT @IASLC: How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, @clarissamathias moderates a discussion w….
0
12
0
RT @StephenVLiu: Phase II study of cabozantinib in #MET altered lung cancer @JTOonline from @HaradaGuilherme @alexdrilon (n=28). RR 20% and….
jtocrr.org
Only type I MET tyrosine kinase inhibitors (TKIs) are approved for treating MET-altered NSCLCs. Preclinically, type II TKIs, such as cabozantinib, can rescue progression on type I TKIs. This phase 2...
0
2
0
RT @BiagioRicciutMD: #MET kinase domain mutations can drive off-target resistance to targeted therapies in #NSCLC. In this study led by #Sh….
jto.org
MET tyrosine kinase domain (TKD) mutations have recently been characterized as de novo oncogenic drivers in NSCLC. Nevertheless, whether activating MET TKD mutations can confer resistance to targeted...
0
12
0
RT @NarjustFlorezMD: It has been a long journey BUT now I .Comfortable wearing yellow I stage. Dare to be different, dare to be YOU! . @L….
0
2
0
RT @alexdrilon: In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now c….
0
2
0
RT @pecci_federica1: Glad to share our paper just published in @CD_AACR that characterizes mutations in the MET kinase domain in lung cance….
aacrjournals.org
Activating MET tyrosine kinase domain mutations were detected across diverse cancer types and showed sensitivity to several MET inhibitors, suggesting that this newly characterized molecular cancer...
0
19
0
RT @GBOT_Alerta: 🧐Impacto das variantes de ALK e co-mutações nos padrões de resistência adquirida e sobrevida. Mutações em TP53 e perda de….
pubmed.ncbi.nlm.nih.gov
In a large-scale, contemporary cohort of patients with advanced ALK-positive NSCLC, we evaluated molecular characteristics and their impact on acquired resistance mutations and clinical outcomes. Our...
0
2
0
RT @LACOG_group: It is a pleasure to introduce to you the new board and steering committee of the LACOG Lung Group. The new formation of t….
0
6
0
RT @BiagioRicciutMD: Had a great time and thoughtful conversations on the current & future role of ADCs in #NSCLC w/ terrific Brazilian col….
0
7
0
RT @BiagioRicciutMD: 🚨🚨Wild-type RET amplification represents a potentially targetable subset of cancer. This repor….
ascopubs.org
PURPOSERET rearrangements and RET activating point mutations represent targetable genomic alterations in advanced solid tumors. However, the frequency and clinicopathologic characteristics of...
0
10
0
RT @BrasilOncologia: 📣Neste vídeo, Dr. Guilherme Harada, comenta os dados do estudo DESTINY-PanTumor01, que mostrou que T-DXd demonstra bo….
0
4
0
RT @StephenVLiu: #ESMO23 Phase II study of cabozantinib in #MET altered (mostly ex14) NSCLC (85% post MET TKI). Cabo is a type II inhibitor….
0
4
0
RT @EmilianoCocco2: Great presentation by Paola Roa from the Cocco lab about the preclinical activity of zurletrectinib, a novel next-gen….
0
3
0
RT @BrasilOncologia: 📣Vem aí Agnostic Talks!. Nesta primeira sessão, Dr. Guilherme Harada e Dr. Marcelo Corassa comentarão os conceitos abo….
0
3
0
What an honor to have you here! Thank you for joining us!.
⭐️Amazing time⭐️ with my stellar thoracic med onc colleagues discussing #NSCLC treatment @HaradaGuilherme @MarceloCorassa in Brazil 🇧🇷
0
1
15
RT @BrasilOncologia: 📣Não perca a cobertura que realizaremos no Congresso ESMO® 2023!. 🔬Acompanhe nossas redes sociais e site para as princ….
0
2
0
RT @FernandoOnco: #molecular alterations in #nsclc #lcsm more targets more effective therapies #pathologist and #oncologist together agains….
0
2
0
Honored to be part of this section at #ASCO23 with this stellar group!.
Fun discussion on navigating fellowship-career transition w/ fellow TECAG membr @AmandaNizamMD @HaradaGuilherme @SurbhiSidanaMD moderated by @jatwanikaran in trainee lounge at #ASCO23. These are impt decisions but don't make them in a vacuum! Talk to family, mentors and yourself!
1
0
19
RT @ahluMD2023: Fantastic discussion by @HaradaGuilherme, @AmandaNizamMD,.@SurbhiSidanaMD,.@Joshua_Reuss on the transition from fellowship….
0
1
0